Lilly to seek FDA approval for new drug for Alzheimer’s disease
Jun 25, 2021
Donanemab already has received a ‘breakthrough therapy’ designation from the FDA.
ARIA described from clinical trials of aducanumab for Alzheimer’s disease
Dec 10, 2021
Amyloid-related imaging abnormalities-edema seen on brain MRI was the most common adverse event in participants receiving high-dose aducanumab (Aduhelm).
Vestibular system impairment tied to fall risk in Alzheimer’s patients
Mar 18, 2022
A significant association was seen between semicircular canal function with lower likelihood of falls in adjusted analysis.
AAN: Higher fitness level tied to lower Alzheimer’s disease risk
Feb 28, 2022
A graded association was seen between levels of cardiorespiratory fitness and the incidence of Alzheimer’s disease and related disorders.
Few older adults knowledgeable about aducanumab for Alzheimer’s disease
Feb 25, 2022
Less than one-quarter of older adults report they would want to take aducanumab (Aduhelm).
Biden makes another push for cancer moonshot initiative
Sep 13, 2022
The president likened JFK’s space race to his own effort to slash cancer rates by 50% in the next 25 years.
Medicare may rethink premium hike for pricey Alzheimer’s drug
Jan 10, 2022
The announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.
Midlife cardiovascular conditions, risk factors linked to cognitive decline
Jan 06, 2022
Most cardiovascular conditions more strongly linked to cognition among women.
Biden pledges to lower prescription drug prices for Americans
Dec 07, 2021
But the biggest policy change — letting Medicare negotiate prices for prescription drugs — will not start to lower costs until 2025.
Trial begins of nasal vaccine for Alzheimer’s disease
Nov 18, 2021
Phase 1 trial will include 16 patients ages 60 to 85 years who have early, symptomatic Alzheimer disease but are otherwise in good health